ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) traded at $3.28 at last check on Tuesday, Jun 30, making an upward move of 2.18% on its previous day’s price.
Looking at the stock we see that its previous close was $3.21 and the beta (5Y monthly) reads 2.55 with the day’s price range being $3.1600 – 3.2950. In terms of its 52-week price range, ZIOP has a high of $7.25 and a low of $1.8. The company’s stock has gained about 8.97% over that past 30 days.
On the other hand, looking at the outlook for the ZIOP stock, short term indicators assign the stock an average of 25% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 7 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the ZIOPHARM Oncology, Inc. (ZIOP) stock as a Hold, while 5 rate it as a Buy. 1 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the ZIOP stock currently stands at 0, and the current price level is 0.1% off its SMA20 and 7.4% from its 50-day simple moving average. The RSI (14) is pointing at 51.71 while the volatility over the past week is 9.41% and drops to 7.91% over the past one month. The beta value is 2.56, while the average true range (ATR) is currently pointing at 0.28. The average price target for the stock over the next 12 months is $5.93, with the estimates having a low of $3 and a high of $7.5. These price ends are -8.54% and +128.66% off the current price level respectively, although investors could be excited at the prospect of a +82.93% if the ZIOP share price touches on the median price of $6.
Let’s briefly compare ZIOPHARM (ZIOP) stock to its peers. We find that today’s price change of +2.18% and -40.47% over the past 12 months for ZIOP competes that of Amgen Inc (AMGN), which has seen its stock price rise 1.86% in the latest trading session and is +26.57% over the last one year. Another of its peers Gilead Sciences Inc (GILD) has climbed 3.19% today, and is +13.43% up over the past year, while Vertex Pharmaceutic (VRTX) is also up 2.18% yet its price remains in the red at -40.47% over the same period. Amgen has a P/E ratio of 18.48 compared to ZIOPHARM’s 0 and Gilead’s 19.78. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.85% and 1.54%, respectively, in early deals.
Coming back to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), we note that the average 3-month trading volume was 1.93 Million, while that of the preceding 10-day period stands at 3.42 Million. Current shares outstanding are 214.29 Million.
According to data from Thomson Reuters, insiders hold 7.12% of the company’s shares while institutions hold 48.07%. The data shows that short shares as of June 14, 2020, stood at 25.03 Million at a short ratio of 12.33. This represents a 11.68% Short interest in Shares outstanding on June 14, 2020. Shares short dropped in June from the previous month at 25.7 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -30.51% down in year-to-date price movement.